Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors as Adjunct Therapy to Statins: A New Frontier in Cardiovascular Risk Reduction. [PDF]
Lamia TH+12 more
europepmc +1 more source
Expression of Concern: Proprotein Convertase 1/3 (PC1/3) in the Rat Alveolar Macrophage Cell Line NR8383: Localization, Trafficking and Effects on Cytokine Secretion. [PDF]
PLOS ONE Editors.
europepmc +1 more source
Statins, but not proprotein convertase subtilisin-kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low-density lipoprotein receptor upregulation. [PDF]
Tan L+8 more
europepmc +1 more source
Early and short-term use of proprotein convertase anti-subtilisin-kexin type 9 inhibitors on coronary plaque stability in acute coronary syndrome. [PDF]
Uehara H+5 more
europepmc +1 more source
The role of proprotein convertase subtilisin/kexin 9 (PCSK9) in macrophage activation: a focus on its LDL receptor-independent mechanisms. [PDF]
Katsuki S, Jha PK, Aikawa E, Aikawa M.
europepmc +1 more source
Proprotein convertase subtilisin/kexin type 4 in mammalian fertility: a review
Charles Gyamera‐Acheampong+1 more
openalex +1 more source